Human Proprotein Convertase 9/PCSK9 Quantikine

Total Page:16

File Type:pdf, Size:1020Kb

Human Proprotein Convertase 9/PCSK9 Quantikine Quantikine® ELISA Human Proprotein Convertase 9/PCSK9 Immunoassay Catalog Number DPC900 Catalog Number SPC900 Catalog Number PDPC900 For the quantitative determination of human Proprotein Convertase Subtilisin Kexin 9 (PCSK9) concentrations in cell culture supernates, cell lysates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 PHARMPAK CONTENTS .......................................................................................................................................................4 OTHER SUPPLIES REQUIRED .............................................................................................................................................5 SUPPLIES REQUIRED FOR CELL LYSATE SAMPLES ...................................................................................................5 PRECAUTIONS .........................................................................................................................................................................5 SAMPLE COLLECTION & STORAGE .................................................................................................................................6 SAMPLE PREPARATION........................................................................................................................................................6 CELL LYSIS PROCEDURE ......................................................................................................................................................6 REAGENT PREPARATION .....................................................................................................................................................7 ASSAY PROCEDURE .............................................................................................................................................................8 CALCULATION OF RESULTS ...............................................................................................................................................9 TYPICAL DATA .........................................................................................................................................................................9 PRECISION ............................................................................................................................................................................. 10 RECOVERY.............................................................................................................................................................................. 10 LINEARITY .............................................................................................................................................................................. 10 SENSITIVITY .......................................................................................................................................................................... 11 CALIBRATION ....................................................................................................................................................................... 11 SAMPLE VALUES .................................................................................................................................................................. 11 SPECIFICITY ........................................................................................................................................................................... 12 REFERENCES ......................................................................................................................................................................... 12 PLATE LAYOUT ..................................................................................................................................................................... 13 Manufactured and Distributed by: USA R&D Systems, Inc. 614 McKinley Place NE, Minneapolis, MN 55413 TEL: 800 343 7475 612 379 2956 FAX: 612 656 4400 E-MAIL: [email protected] Distributed by: Europe | Middle East | Africa Bio-Techne Ltd. China Bio-Techne China Co., Ltd. 19 Barton Lane, Abingdon Science Park Unit 1901, Tower 3, Raffles City Changning Office, Abingdon OX14 3NB, UK 1193 Changning Road, Shanghai PRC 200051 TEL: +44 (0)1235 529449 TEL: +86 (21) 52380373 (400) 821-3475 FAX: +44 (0)1235 533420 FAX: +86 (21) 52371001 E-MAIL: [email protected] E-MAIL: [email protected] INTRODUCTION Proprotein convertase subtilisin kexin 9 (PCSK9), also named neural apoptosis-regulated convertase 1 (NARC-1), is a member of the proteinase K subfamily of subtilisin-related serine endoproteases. The full-length protein has 692 amino acids, including a signal peptide, a pro- domain, and a catalytic domain. PCSK9 is highly expressed in the liver, intestine, and kidney. It is initially synthesized as a soluble 74 kDa precursor protein. In the endoplasmic reticulum, it undergoes autocatalytic intramolecular cleavage to generate a 14 kDa pro- domain and a 60 kDa catalytic domain. These two domains remain associated when PCSK9 is secreted outside the cells (1-3). The primary physiologic function of PCSK9 is to mediate the degradation of low density lipoprotein receptor (LDL R). Early observations indicated that gain-of-function missense mutations in the PCSK9 gene can cause an autosomal dominant form of hypercholesterolemia (4, 5). The expression of PCSK9 was observed to be up-regulated by the sterol regulatory element binding proteins (SREBPs), a family of transcription factors that are responsible for the upregulation of genes involved in cholesterol and fatty acid metabolism, such as the LDL R gene (6, 7). Further experimental evidence revealed that in mice, when the PCSK9 gene was knocked out, the number of LDL R in hepatocytes increased, whereas when PCSK9 was over-expressed, the amount of LDL R protein was reduced in the liver (8, 9). In humans, genetic analyses have shown that individuals who have nonsense or loss-of-function mutations in the PCSK9 gene have significantly lower plasma LDL cholesterol levels (10, 11). These investigations clearly indicated that PCSK9 plays a key role in reducing the hepatic LDL R levels. Recently, the underlying mechanism has been uncovered: under normal physiologic conditions, the LDL R is internalized on the cell surface and directed to the endosomes in order to be recycled back to the cell surface. PCSK9 binds to the EGF domain of the LDL R and prevents LDL R from being sorted to the endosomes. Instead, the PCSK9/LDL R complex is redistributed to the lysosomes for degradation (12-14). As such, PCSK9 regulates the amount of LDL R in the circulation and modulates cholesterol levels. Serum PCSK9 concentrations have been found to be directly associated with cholesterol levels (15, 16). Since individuals with loss-of-function PCSK9 mutations have strikingly reduced risk of coronary heart diseases, PCSK9 has become an attractive drug target in recent years (17, 18). One approach is to generate small molecules that are able to interfere with PCSK9 autoactivation and its interaction with LDL R. Other approaches aiming to reduce the amounts of PCSK9 in the circulation, such as small interfering RNAs (siRNAs), have also shown promise (19, 20). The Quantikine® Human Proprotein Convertase 9/PCSK9 Immunoassay is a 4.5 hour solid phase ELISA designed to measure human PCSK9 in cell culture supernates, cell lysates, serum, and plasma. It contains NS0-expressed recombinant human PCSK9 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural PCSK9 showed linear curves that were parallel to the standard curves obtained using the Quantikine® kit standards. These results indicate that this kit can be used to determine relative mass values for natural human PCSK9. www.RnDSystems.com 1 PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human PCSK9 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any PCSK9 present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for human PCSK9 is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of PCSK9 bound in the initial step. The color development is stopped and the intensity of the color is measured. LIMITATIONS OF THE PROCEDURE • FOR RESEARCH USE ONLY. NOT FOR USE
Recommended publications
  • The Secretory Proprotein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation
    The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation Nabil G. Seidah*†, Suzanne Benjannet*, Louise Wickham*, Jadwiga Marcinkiewicz*, Ste´phanie Be´langer Jasmin‡, Stefano Stifani‡, Ajoy Basak§, Annik Prat*, and Michel Chre´ tien§ *Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC, H2W 1R7 Canada; ‡Montreal Neurological Institute, McGill University, Montreal, QC, H3A 2B4 Canada; and §Regional Protein Chemistry Center and Diseases of Aging Unit, Ottawa Health Research Institute, Ottawa Hospital, Civic Campus, 725 Parkdale Avenue, Ottawa, ON, K1Y 4E9 Canada Edited by Donald F. Steiner, University of Chicago, Chicago, IL, and approved December 5, 2002 (received for review September 10, 2002) Seven secretory mammalian kexin-like subtilases have been iden- LP251 (Eli Lilly, patent no. WO 02͞14358 A2) recently cloned tified that cleave a variety of precursor proteins at monobasic and by two pharmaceutical companies. NARC-1 was identified via dibasic residues. The recently characterized pyrolysin-like subtilase the cloning of cDNAs up-regulated after apoptosis induced by SKI-1 cleaves proproteins at nonbasic residues. In this work we serum deprivation in primary cerebellar neurons, whereas LP251 describe the properties of a proteinase K-like subtilase, neural was discovered via global cloning of secretory proteins. Aside apoptosis-regulated convertase 1 (NARC-1), representing the ninth from the fact that NARC-1 mRNA is expressed in liver ϾϾ member of the secretory subtilase family. Biosynthetic and micro- testis Ͼ kidney and that the gene localizes to human chromo- sequencing analyses of WT and mutant enzyme revealed that some 1p33-p34.3, no information is available on NARC-1 ac- human and mouse pro-NARC-1 are autocatalytically and intramo- tivity, cleavage specificity, cellular and tissue expression, and lecularly processed into NARC-1 at the (Y,I)VV(V,L)(L,M)2 motif, a biological function.
    [Show full text]
  • Proteinase K Dna Extraction Protocol
    FT-85870n Proteinase K Product data Proteinase K, from Tritirachium album timber (Engyodontium album) Syn.: peptidase K, Tritirachium alkaline proteinase Protein K powder #858706 Proteinase K solution #718961 CAS: [ 39450-01-6 ] MW: 8,900 daltons (28.9 kDa). primary sequence for proteinase K: GAAQTNAPWGLARISSTSPGTSTYYYDESAGQGSCVYVIDTGIEASHPEF EGRAQMVKTYYYSSRDGNGHGTHCAGTVGSRTYGVAKKTQLFGVKVLDDN GSGQYSTIIAGMDFVASDKNNRNCPKGVVASLSLGGGYSSSVNSAAARLQ SSGVMVAVAAGNNNADARNYSPASEPSVCTVGASDRYDRRSSFSNYGSVL DIFGPGTSILSTWIGGSTRSISGTSMATPHVAGLAAYLMTLGKTTAASAC Proteinase K Protein Structure RYIADTANKGDLSNIPFGTVNLLAYNNYQA FAQ & Technical tips What is Proteinase K? PProteinase K (also protease K or endopeptidase K) is a broad-spectrum serine protease widely used in molecular biology. Proteinase K is able to digest native keratin (hair), hence, the name “Proteinase K”. It is commonly used because of its broad specificity, that makes it useful to clean nucleic acid complexe samples and to lyse cells. It has been used for isolation of mRNA, high molecular weight DNA and to inactivate other enzymatic activities. The enzyme was discovered in 1974 in extracts of the fungus Engyodontium album (formerly Tritirachium album). What are proteinase K applications? Proteinase K is ideal for many molecular biology applications because it is able to break down proteins and inactivate DNases and RNases that would otherwise degrade a desired sample of DNA or RNA. - Digestion of unwanted proteins in molecular biology applications - Removal of endotoxins bound to cationic proteins such as lysozyme and RNaseA - Removal of nucleases for in situ hybridization - Prion research with respect to TSE (transmissible spongiform encephalopathies) - Protease footprinting - Mitochontrial isolation - Isolation of genomic DNA - Isolation of cytoplasmic RNA - Isolation of highly native DNA or RNA Proteinase K is commonly used in molecular biology to digest protein and remove contamination from preparations of nucleic acid.
    [Show full text]
  • Molecular Markers of Serine Protease Evolution
    The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages.
    [Show full text]
  • Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: a Comparative in Situ Hybridization Analysis
    The Journal of Neuroscience, March 1993. 73(3): 1258-1279 Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: A Comparative in situ Hybridization Analysis Martin K.-H. Schafer,i-a Robert Day,* William E. Cullinan,’ Michel Chri?tien,3 Nabil G. Seidah,* and Stanley J. Watson’ ‘Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan 48109-0720 and J. A. DeSeve Laboratory of *Biochemical and 3Molecular Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada H2W lR7 Posttranslational processing of proproteins and prohor- The participation of neuropeptides in the modulation of a va- mones is an essential step in the formation of bioactive riety of CNS functions is well established. Many neuropeptides peptides, which is of particular importance in the nervous are synthesized as inactive precursor proteins, which undergo system. Following a long search for the enzymes responsible an enzymatic cascade of posttranslational processing and mod- for protein precursor cleavage, a family of Kexin/subtilisin- ification events during their intracellular transport before the like convertases known as PCl, PC2, and furin have recently final bioactive products are secreted and act at either pre- or been characterized in mammalian species. Their presence postsynaptic receptors. Initial endoproteolytic cleavage occurs in endocrine and neuroendocrine tissues has been dem- C-terminal to pairs of basic amino acids such as lysine-arginine onstrated. This study examines the mRNA distribution of (Docherty and Steiner, 1982) and is followed by the removal these convertases in the rat CNS and compares their ex- of the basic residues by exopeptidases. Further modifications pression with the previously characterized processing en- can occur in the form of N-terminal acetylation or C-terminal zymes carboxypeptidase E (CPE) and peptidylglycine a-am- amidation, which is essential for the bioactivity of many neu- idating monooxygenase (PAM) using in situ hybridization ropeptides.
    [Show full text]
  • PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different
    Journal of Clinical Medicine Article PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy Kari A. Mäkelä 1,*, Jari Jokelainen 2 , Ville Stenbäck 1,3, Juha Auvinen 2, Marjo-Riitta Järvelin 2,4,5, Mikko Tulppo 1, Juhani Leppäluoto 1, Sirkka Keinänen-Kiukaanniemi 2 and Karl-Heinz Herzig 1,6,* 1 Research Unit of Biomedicine, Medical Research Center, Faculty of Medicine, University of Oulu and Oulu University Hospital, 90014 Oulu, Finland; ville.stenback@oulu.fi (V.S.); mikko.tulppo@oulu.fi (M.T.); juhani.leppaluoto@oulu.fi (J.L.) 2 Center for Life Course Health Research and Medical Research Center, Faculty of Medicine, University of Oulu and Oulu University Hospital, 90014 Oulu, Finland; jari.jokelainen@oulu.fi (J.J.); juha.auvinen@oulu.fi (J.A.); [email protected] (M.-R.J.); sirkka.keinanen-kiukaanniemi@oulu.fi (S.K.-K.) 3 Biocenter Oulu, University of Oulu, 90014 Oulu, Finland 4 MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, St Mary’s Campus, Norfolk Place, London W2 1PG, UK 5 Unit of Primary Care, Oulu University Hospital, 90029 Oulu, Finland 6 Institute of Pediatrics, Poznan University of Medical Sciences, 60-512 Poznan, Poland * Correspondence: kari.makela@oulu.fi (K.A.M.); karl-heinz.herzig@oulu.fi (K.-H.H.); Tel.: +358-294-48-5274 (K.A.M.) Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) degrades low-density lipoprotein Citation: Mäkelä, K.A.; Jokelainen, J.; cholesterol (LDL-C) receptors, and thus regulates the LDL-C levels in the circulation.
    [Show full text]
  • PCSK9 Inhibitor Non-Response in a Patient with Preserved LDL Receptor
    PCSK9 inhibitor non-response in a patient with preserved LDL receptor function: A case study Losh C, Underberg J Murray Hill Medical Group and New York University School of Medicine, New York, NY Background Results Conclusions PCSK9 inhibitors (PCSK9Is) are monoclonal LDL-C levels after three and seven weeks Absence of LDL receptor activity is not the antibodies that bind to serum PCSK9 and Response to Statin Therapy of therapy with alirocumab 75 mg were 235 only mechanism of PCSK9 inhibitor non- delay LDL receptor degradation. Two mg/dL and 239 mg/dL respectively. Three response. An alteration in the PCSK9 PCSK9Is are commercially available: and seven weeks after up-titration, LDL-C Intervention LDL-C (mg/dL) Change (%) evolocumab and alirocumab. FDA approved binding site for alirocumab and indications include LDL cholesterol (LDL-C) was 249 mg/dL and 292 mg/dL, evolocumab is proposed as a hypothetical lowering on maximally tolerated statin respectively. Total duration of alirocumab None 283 — mechanism for non-response in this therapy was 16 weeks. LDL-C was 253 therapy in patients with ASCVD and Familial patient. Other alternatives include Hypercholesterolemia (FH). Among patients mg/dL after 3 weeks of therapy with pitavastatin 2 mg 238 -15.9% immunogenicity, noncompliance, or faulty with LDL receptor mutations, those with evolocumab, at which time PCSK9 1 dose/week partial loss of function typically respond well inhibitor therapy was discontinued due to pitavastatin 2 mg injection techniqueReferences. 216 -23.7% to PCSK9 inhibition, while those with lack of clinical response. 2 doses/week Amgen Inc. (2015). Repatha: Highlights of homozygous receptor-negative mutations, pitavastatin 2 mg ie.
    [Show full text]
  • Human Pcsk9 (Proprotein Convertase Subtilisin/Kexin Type 9) Elisa
    QUANTITATIVE DETERMINATION NEW PRODUCT OF HUMAN PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) ELISA Human PCSK9 (Proprotein convertase subtilisin/kexin type 9) ELISA High sensitivity (9 pg/ml) Excellent analytical characteristics Validated for human serum and plasma samples (EDTA, citrate, heparin) CARDIOVASCULAR DISEASE DIABETOLOGY LIPOPROTEIN METABOLISM HUMAN PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) ELISA Introduction Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a decreased clearance of serum cholesterol, and as a result a serine protease that plays an important role in the regulation higher risk of hypercholesterolemia. of serum low-density lipoprotein (LDL) cholesterol by downregulation of LDL receptor, and as such is considered a Human genetic studies have shown that “gain-of-function” novel target in cholesterol lowering therapy. LDL cholesterol (GOF) mutations in the PCSK9 gene can lead to a form (LDL-C) binds to LDL receptors (LDLRs) on the surface of of familial hypercholesterolemia with a higher risk of hepatic cell where the complex is internalized and transported cardiovascular disease. In contrast, humans with “loss- to the endosome. LDL-C dissociates from the receptor and is of-function” (LOF) mutations in the PCSK9 gene have catabolized whereas the LDLR is recycled to the cell surface lower serum cholesterol levels and a lower incidence of for continued clearance of serum cholesterol. PCSK9 affects cardiovascular disease. Thus PCSK9 had a key impact not only the receptor recycling pathway by binding to the LDLR and on circulating LDL-C level but also on cardiovascular risk and causing degradation of the receptor within the endosome/ atherosclerotic process. lysosome compartment.
    [Show full text]
  • Co-Segregation of PCSK9 Gene I474V Variant with Diabetic And
    Available online at www.ijmrhs.com International Journal of Medical Research & ISSN No: 2319-5886 Health Sciences, 2017, 6(6): 100-105 Co-Segregation of PCSK9 Gene I474V Variant with Diabetic and Hypercholesterolemic Subjects Edem Nuglozeh1* and Nabil A Hasona1,2 1 Department of Biochemistry, College of Medicine, University of Hail, Hail, Saudi Arabia 2 Faculty of Science, Chemistry Department, Biochemistry Division, Beni-Suef University, Beni-Suef, Egypt *Corresponding e-mail: [email protected] ABSTRACT PCSK-9 has a tremendous role in lipid metabolism. PCSK9 variants have been concomitantly linked to alterations in plasma lipid profile, leading to increased risk of cardiovascular disease and diabetes mellitus. The aim of our study was to determine the frequency of PCSK-9 I474V variant in hypercholesterolemic and diabetic subjects. Plasma lipid profile and fasting blood glucose were assayed in 30 healthy, 25 hypercholesterolemic, and 45 diabetic subjects. Genomic DNA was extracted from whole blood and PCR was run using specific primers to obtain an amplicon harbouring exon 9. The amplicon was later subjected to Sanger sequencing and. A missense mutation of PCSK9 I474V SNP was detected in the exon 9 of PCSK9 gene. Our results show a frequency of the PCSK9 I474V SNP in Hail region of Saudi Arabia and this frequency is higher among hypercholesterolemic and diabetic patients. To our best knowledge, this is the first report of mutation of this nature in Hail region of Saudi Arabia. Keywords: PCSK-9, I474V, hypercholesterolemia, diabetes, genomic DNA, mutation, Hail, Saudi Arabia. INTRODUCTION Genetic and epidemiological records have revealed the link between plasma levels of LDL and HDL cholesterol, and cardiovascular disease incidence all over the world [1]; although lifestyle, diet, and physical activity have a role in shaping individual lipid profiles, it is clear that lipid profile is strongly linked to genetic variations.
    [Show full text]
  • Variants of PCSK9 Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans
    diagnostics Article Variants of PCSK9 Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans. The GEA Project Erasmo Zamarrón-Licona 1,† , José Manuel Rodríguez-Pérez 1,† , Rosalinda Posadas-Sánchez 2 , Gilberto Vargas-Alarcón 1 , Manuel Alfonso Baños-González 3 , Verónica Marusa Borgonio-Cuadra 4 and Nonanzit Pérez-Hernández 1,* 1 Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico; [email protected] (E.Z.-L.); [email protected] (J.M.R.-P.); [email protected] (G.V.-A.) 2 Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico; [email protected] 3 Centro de Investigación y Posgrado, División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa 86150, Mexico; [email protected] 4 Departamento de Genética, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Ciudad de México 14389, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +52-55-55732911 (ext. 26301) † These authors contributed equally to this work. Citation: Zamarrón-Licona, E.; Abstract: Background: Coronary artery disease (CAD) is a chronic, inflammatory, and complex Rodríguez-Pérez, J.M.; disease associated with vascular risk factors. Nowadays, the coronary artery calcium (CAC) is Posadas-Sánchez, R.; Vargas-Alarcón, a specific marker of the presence and extent of atherosclerosis. Additionally, CAC is a predictor G.; Baños-González, M.A.; of future coronary events in asymptomatic individuals diagnosed with subclinical atherosclerosis Borgonio-Cuadra, V.M.; (CAC > 0). In this study, our aim is to evaluate the participation of two polymorphisms of the PCSK9 Pérez-Hernández, N.
    [Show full text]
  • Enzymes for Cell Dissociation and Lysis
    Issue 2, 2006 FOR LIFE SCIENCE RESEARCH DETACHMENT OF CULTURED CELLS LYSIS AND PROTOPLAST PREPARATION OF: Yeast Bacteria Plant Cells PERMEABILIZATION OF MAMMALIAN CELLS MITOCHONDRIA ISOLATION Schematic representation of plant and bacterial cell wall structure. Foreground: Plant cell wall structure Background: Bacterial cell wall structure Enzymes for Cell Dissociation and Lysis sigma-aldrich.com The Sigma Aldrich Web site offers several new tools to help fuel your metabolomics and nutrition research FOR LIFE SCIENCE RESEARCH Issue 2, 2006 Sigma-Aldrich Corporation 3050 Spruce Avenue St. Louis, MO 63103 Table of Contents The new Metabolomics Resource Center at: Enzymes for Cell Dissociation and Lysis sigma-aldrich.com/metpath Sigma-Aldrich is proud of our continuing alliance with the Enzymes for Cell Detachment International Union of Biochemistry and Molecular Biology. Together and Tissue Dissociation Collagenase ..........................................................1 we produce, animate and publish the Nicholson Metabolic Pathway Hyaluronidase ...................................................... 7 Charts, created and continually updated by Dr. Donald Nicholson. DNase ................................................................. 8 These classic resources can be downloaded from the Sigma-Aldrich Elastase ............................................................... 9 Web site as PDF or GIF files at no charge. This site also features our Papain ................................................................10 Protease Type XIV
    [Show full text]
  • Irf2)Intrypsinogen5 Gene Transcription
    Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2)intrypsinogen5 gene transcription Hideki Hayashia, Tomoko Kohnoa, Kiyoshi Yasuia, Hiroyuki Murotab, Tohru Kimurac, Gordon S. Duncand, Tomoki Nakashimae, Kazuo Yamamotod, Ichiro Katayamab, Yuhua Maa, Koon Jiew Chuaa, Takashi Suematsua, Isao Shimokawaf, Shizuo Akirag, Yoshinao Kuboa, Tak Wah Makd,1, and Toshifumi Matsuyamaa,h,1 aDivision of Cytokine Signaling, Department of Molecular Biology and Immunology and fDepartment of Investigative Pathology, Nagasaki University Graduate School of Biomedical Science, Nagasaki 852-8523, Japan; Departments of bDermatology and cPathology, Graduate School of Medicine and gDepartment of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan; dCampbell Family Cancer Research Institute, Princess Margaret Hospital, Toronto, ON, Canada M5G 2M9; eDepartment of Cell Signaling, Tokyo Medical and Dental University, Tokyo 113-8549, Japan; and hGlobal Center of Excellence Program, Nagasaki University, Nagasaki 852-8523, Japan Contributed by Tak Wah Mak, October 5, 2011 (sent for review September 8, 2011) − − Mice deficient for interferon regulatory factor (Irf)2 (Irf2 / mice) transcriptional activation of dsRNA-sensing PRRs were critical for exhibit immunological abnormalities and cannot survive lympho- the pIC-induced death. cytic choriomeningitis virus infection. The pancreas of these ani- mals is highly inflamed, a phenotype replicated by treatment with Results and Discussion − − poly(I:C), a synthetic double-stranded RNA. Trypsinogen5 mRNA Irf2 / Mice Show IFN-Dependent Poly(I:C)-Induced Pancreatitis and −/− IFN-Independent Secretory Dysfunction in Pancreatic Acinar Cells. was constitutively up-regulated about 1,000-fold in Irf2 mice − − LCMV-infected Irf2 / mice die within 4 wk postinfection (3), compared with controls as assessed by quantitative RT-PCR.
    [Show full text]
  • A Role for Urokinase-Type Plasminogen Activator in Human Immunodeficiency Virus Type 1 Infection of Macrophages
    JOURNAL OF VIROLOGY, July 1996, p. 4451–4456 Vol. 70, No. 7 0022-538X/96/$04.0010 Copyright q 1996, American Society for Microbiology A Role for Urokinase-Type Plasminogen Activator in Human Immunodeficiency Virus Type 1 Infection of Macrophages 1 2 3 MARK A. HANDLEY, † ROY T. STEIGBIGEL, AND SIDONIE A. MORRISON * Department of Pharmacology,1 and Divisions of Infectious Diseases2 and Hematology,3 Department of Medicine, University Medical Center at Stony Brook, Stony Brook, New York Received 17 July 1995/Accepted 12 April 1996 Urokinase-type plasminogen activator (uPA), a proteinase which activates plasminogen by cleaving at -CPGR2V-, was shown to cleave the V3 loop in recombinant gp120 of human immunodeficiency virus type 1 (HIV-1) IIIB and MN strains, as well as a synthetic, cyclized peptide representing the clade B consensus sequence of V3. Proteolysis occurred at the homologous -GPGR2A-, an important neutralizing determinant of HIV-1. It required soluble CD4 and was prevented by inhibitors of uPA but not by inhibitors of likely contaminating plasma proteinases. It was accelerated by heparin, a known cofactor for plasminogen activation. In immune capture experiments, tight binding of uPA to viral particles, which did not depend on CD4, was also demonstrated. Active site-directed inhibitors of uPA diminished this binding, as did a neutralizing antibody to V3. Addition of exogenous uPA to the laboratory-adapted IIIB strain of HIV-1, the macrophage-tropic field strains JR-CSF and SF-162, or a fresh patient isolate of indeterminate tropism, followed by infection of macrophages with the various treated viruses, resulted in severalfold increases in subsequent viral replication, as judged by yields of reverse transcriptase activity and p24 antigen, as well as incorporation, as judged by PCR in situ.
    [Show full text]